Peripheral Vasodilators

DrugDrug NameDrug Indication
DB08162FasudilNot Available
DB01049Ergoloid mesylateIt was labeled by the FDA for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible condition[A32913] as well as for age-related cognitive impairment.[A32926] The prescription of this drug is conditioned to the corroboration that the patient is not suffering from a potentially reversible and treatable condition especially delirium and dementiform illness secondary to systemic disease, primary neurological disease or primary mood disturbance.[L2637] To know more about the individual components of the ergoloid mixture, please visit [DB13345] and [DB11274]
DB00627NiacinNiacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections.[L7550,L7553,L7556,L7559] Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia.[L7562,L7565] It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia.[L7562,L7565] Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia.[L7562,L7565] Finally niacin is indicated to treat severe hypertriglyceridemia.[L7562,L7565]
DB00692PhentolamineUsed as an aid for the diagnosis of pheochromocytoma, and may be administered immediately prior to or during pheochromocytomectomy to prevent or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor. Phentolamine has also been used to treat hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs in patients taking MAO inhibitors, or by clonidine withdrawal syndrome. Other indications include the prevention of dermal necrosis and sloughing following IV administration or extravasation of norepinephrine, decrease in impedance to left ventricular ejection and the infarct size in patients with MI associated with left ventricular failure, treatment of erectile dysfunction through self-injection of small doses combined with papaverine hydrochloride into the corpus cavernosum, and as an adjunct to the management of cocaine overdose to reverse coronary vasoconstriction following use of oxygen, benzodiazepines,and nitroglycerin.
DB00699NicergolineFor the treatment of senile dementia, migraines of vascular origin, transient ischemia, platelet hyper-aggregability, and macular degeneration.
DB00797TolazolineFor the treatment of pulmonary artery anomalies
DB00806PentoxifyllineFor the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
DB00925PhenoxybenzamineFor the treatment of phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension.
DB04838CyclandelateUsed in the treatment of various blood vessel diseases (e.g., claudication, arteriosclerosis and Raynaud's disease) and nighttime leg cramps.
DB06152NylidrinNylidrin is mainly indicated in conditions like arteriosclerosis, cerebrovascular disease, peripheral vascular disease, Raynaud's disease, thrombo-angitis obliterans, and thrombophlebitis [L2285]. It may sometimes be used in the treatment of peripheral vascular disorders in addition premature labor (however, the drug is not approved for premature labor)[A32531].
DB08941IsoxsuprineNot Available
DB08949Inositol nicotinateIndicated as a dietary supplement for the source of niacin. Has been investigated for potential beneficial effects on serum lipids. In Europe, inositol hexanicotinate is indicated as a patented drug known as Hexopal, which is therapeutically indicated for the symptomatic relief of severe intermittent claudication and Raynaud’s phenomenon.
DB08954IfenprodilNot Available
DB09092XanthinolXanthinol is primarily used in diet supplements to increase the brain metabolism of glucose and obtain ATP. Xanthinol is also used as an agent to reduced cholesterol as it is a vasodilator.[L1080] Its action allows having an elevated rate of blood flow in the brain which helps improve memory function, concentration and awareness.[L1079] Thus, due to his actions, xanthinol is indicated to improve cerebrovascular and peripheral vascular disorders as well as hyperlipidaemias.[L1081]
DB12123CinepazideNot Available
DB13197KallidinogenaseNot Available
DB13206BamethanNot Available
DB13340SuloctidilNot Available
DB13345DihydroergocristineDihydroergocristine is used in some countries such as Brasil as a single agent for the treatment of cerebral and peripheric vascular events.[L2649] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].
DB13355VisnadineNot Available
DB13374VincamineNot Available
DB13488BencyclaneNot Available
DB13510BuflomedilNot Available
DB13588NaftidrofurylNot Available
DB13634PentifyllineNot Available
DB13681ButalamineNot Available
DB13709CiclonicateNot Available
DB13727AzapetineNot Available
DB13753CetiedilNot Available
DB13793VinburnineNot Available
DB13842Etofylline nicotinateNot Available
DB09205MoxisylyteBy the WHO, moxisylyte is indicated for the symptomatic management of sequelae of cerebral infarction or hemorrhage.[T91] The cerebral infarction is characterized by the blockage of the artery either by the formation of a thrombus or an embolus.[A31644] On the other hand, the FDA classified moxisylyte for the reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma.[L1172] Closed-angle glaucoma is caused by the contact between the iris and the trabecular meshwork. This contact will damage the aqueous outflow by the meshwork thus, increasing eye pressure and producing the symptoms of glaucoma.[A31645] Mydriasis is referred to the dilatation of the pupils and this standard body function is known to be a trigger factor for the development of acute closed-angle glaucoma.This risk is explained by the generation of a pupillary block, which is the contact between the pupillary margins and the lens, thus preventing flow from the aqueous humor to the anterior chamber and followed by an increased pressure gradient.[L1173] Moxisylyte is also approved in France as the first drug for the treatment of impotence.[A31647]
DB04145Nicotinyl alcoholNot Available
DrugDrug NameTargetType
DB08162FasudilcAMP-dependent protein kinase inhibitor alphatarget
DB08162FasudilcAMP-dependent protein kinase catalytic subunit alphatarget
DB08162FasudilRho-associated protein kinase 1target
DB08162FasudilRho-associated protein kinase 2target
DB01049Ergoloid mesylateDopamine receptortarget
DB01049Ergoloid mesylateAlpha adrenergic receptortarget
DB01049Ergoloid mesylateBeta adrenergic receptortarget
DB01049Ergoloid mesylateSerotonin Receptorstarget
DB01049Ergoloid mesylateCytochrome P450 3A4enzyme
DB00627NiacinHydroxycarboxylic acid receptor 2target
DB00627NiacinNicotinamide N-methyltransferasetarget
DB00627NiacinNicotinate-nucleotide pyrophosphorylase [carboxylating]target
DB00627NiacinHydroxycarboxylic acid receptor 3target
DB00627NiacinSolute carrier family 22 member 5transporter
DB00627NiacinSolute carrier organic anion transporter family member 2B1transporter
DB00627NiacinMonocarboxylate transporter 1transporter
DB00627NiacinCytochrome P450 2D6enzyme
DB00627NiacinSodium-coupled monocarboxylate transporter 1transporter
DB00627NiacinMonocarboxylate transporter 4transporter
DB00627NiacinThyroxine-binding globulincarrier
DB00627NiacinCytochrome P450 3A4enzyme
DB00627NiacinCytochrome P450 2E1enzyme
DB00692PhentolamineAlpha-2A adrenergic receptortarget
DB00692PhentolamineAlpha-1A adrenergic receptortarget
DB00692PhentolamineAlpha-1B adrenergic receptortarget
DB00692PhentolamineAlpha-1D adrenergic receptortarget
DB00699NicergolineAlpha-1A adrenergic receptortarget
DB00699NicergolineCytochrome P450 2D6enzyme
DB00797TolazolineAlpha-1A adrenergic receptortarget
DB00797TolazolineAlpha-2A adrenergic receptortarget
DB00797TolazolineHistamine H1 receptortarget
DB00797TolazolineHistamine H2 receptortarget
DB00797TolazolineAlpha-2C adrenergic receptortarget
DB00797TolazolineAlpha-2B adrenergic receptortarget
DB00806PentoxifyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00806PentoxifyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB00806PentoxifyllinecGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00806PentoxifyllineAdenosine receptor A1target
DB00806PentoxifyllineAdenosine receptor A2atarget
DB00806PentoxifyllineCytochrome P450 1A2enzyme
DB00925PhenoxybenzamineAlpha-1A adrenergic receptortarget
DB00925PhenoxybenzamineSolute carrier family 22 member 2transporter
DB00925PhenoxybenzamineSolute carrier family 22 member 1transporter
DB00925PhenoxybenzamineSolute carrier family 22 member 3transporter
DB00925PhenoxybenzamineAlpha-2A adrenergic receptortarget
DB00925PhenoxybenzamineAlpha-2C adrenergic receptortarget
DB00925PhenoxybenzamineAlpha-2B adrenergic receptortarget
DB00925PhenoxybenzamineBeta-2 adrenergic receptortarget
DB00925PhenoxybenzamineAlpha-1B adrenergic receptortarget
DB00925PhenoxybenzamineAlpha-1D adrenergic receptortarget
DB04838CyclandelateVoltage-dependent calcium channel subunit alpha-2/delta-1target
DB04838CyclandelateLiver carboxylesterase 1target
DB04838CyclandelateCytochrome P450 3A4enzyme
DB06152NylidrinCatechol O-methyltransferaseenzyme
DB06152NylidrinVoltage-dependent T-type calcium channel subunit alpha-1Itarget
DB06152NylidrinInterferon alpha/beta receptor 2target
DB06152NylidrinCytochrome P450 3A4enzyme
DB08949Inositol nicotinateSodium-coupled monocarboxylate transporter 1transporter
DB08949Inositol nicotinateATP synthase subunit beta, mitochondrialenzyme
DB08949Inositol nicotinateHydroxycarboxylic acid receptor 3target
DB08949Inositol nicotinateHydroxycarboxylic acid receptor 2target
DB08949Inositol nicotinateDiacylglycerol O-acyltransferase 2enzyme
DB08954IfenprodilGlutamate receptor ionotropic, NMDA 1target
DB08954IfenprodilGlutamate receptor ionotropic, NMDA 2Btarget
DB09092Xanthinol60S ribosomal protein L3target
DB09092XanthinolNAD(P) transhydrogenase, mitochondrialtarget
DB09092XanthinolGlyceraldehyde-3-phosphate dehydrogenasetarget
DB09092XanthinolIsocitrate dehydrogenase [NAD] subunit alpha, mitochondrialtarget
DB09092Xanthinol2-oxoglutarate dehydrogenase, mitochondrialtarget
DB09092XanthinolMalate dehydrogenase, mitochondrialtarget
DB13345DihydroergocristineSerotonin Receptorstarget
DB13345DihydroergocristineBeta adrenergic receptortarget
DB13345DihydroergocristineAlpha adrenergic receptortarget
DB13345DihydroergocristineDopamine receptortarget
DB13345DihydroergocristineBile salt export pumptransporter
DB13345DihydroergocristineCytochrome P450 3A4enzyme
DB13488BencyclaneCytochrome P450 3A4enzyme
DB13634PentifyllineCytochrome P450 1A2enzyme
DB09205MoxisylyteCytochrome p450 3A subfamilyenzyme
DB09205MoxisylyteAlpha adrenergic receptortarget